Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $130.46, but acceptable to hold if already in. Reasons: Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk).
Neurocrine Biosciences is a neuroscience-focused biopharma with FDA-approved treatments for tardive dyskinesia and Huntington's chorea (INGREZZA, $2.51B net sales in 2025), classic CAH (CRENESSITY, $301.2M in first full year 2025), and endometriosis/uterine fibroids (elagolix,... Read more
Hold if already holding. Not a fresh buy at $130.46, but acceptable to hold if already in. Reasons: Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk). Chart setup: Death cross but MACD improving, RSI 58. Growth is outpacing valuation and the chart agrees (PEG 0.43, quality 7.7/10, growth 9.8/10). | News modifier -2 (STRONG_BUY_NOW → HOLD_IF_HOLDING) Score 6.8/10, moderate confidence.
Passes 5/6 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on earnings proximity 4d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductINGREZZA10-K Item 1A: 'Our ability to produce INGREZZA revenues consistent with expectations ultimately depends on our ability to continue to successfully commercialize INGREZZA'
- MEDIUMCustomerconcentrated customers10-K Item 1A: 'Our customers are concentrated and therefore the loss of a significant customer may harm our business.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $130.46, but acceptable to hold if already in. Reasons: Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk). Chart setup: Death cross but MACD improving, RSI 58. Growth is outpacing valuation and the chart agrees (PEG 0.43, quality 7.7/10, growth 9.8/10). | News modifier -2 (STRONG_BUY_NOW → HOLD_IF_HOLDING) Target $167.09 (+28.1%), stop $123.83 (−5.4%), A.R:R 5.4:1. Score 6.8/10, moderate confidence.
Take-profit target: $167.09 (+28.0% upside). Target $167.09 (+28.1%), stop $123.83 (−5.4%), A.R:R 5.4:1. Stop-loss: $123.83.
Concentration risk — Product: INGREZZA; Earnings in 4 days (event risk); Consecutive earnings misses (2).
Neurocrine Biosciences, Inc. trades at a P/E of 28.2 (forward 10.0). TrendMatrix value score: 7.4/10. Verdict: Hold.
36 analysts cover NBIX with a consensus score of 4.2/5. Average price target: $186.
What does Neurocrine Biosciences, Inc. do?Neurocrine Biosciences is a neuroscience-focused biopharma with FDA-approved treatments for tardive dyskinesia and...
Neurocrine Biosciences is a neuroscience-focused biopharma with FDA-approved treatments for tardive dyskinesia and Huntington's chorea (INGREZZA, $2.51B net sales in 2025), classic CAH (CRENESSITY, $301.2M in first full year 2025), and endometriosis/uterine fibroids (elagolix, via AbbVie). INGREZZA represents a significant portion of total net product sales.